
|Videos|August 25, 2017
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
Author(s)Prudence A. Francis, MD
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer.
Advertisement
In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal estrogen receptor (ER)-positive breast cancer.
Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer
2
GLP-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways
3
Mezigdomide Regimen Boosts PFS in Relapsed/Refractory Multiple Myeloma
4
Tazemetostat Withdrawn From Follicular Lymphoma, Sarcoma Markets
5























































